Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial (vol 29, pg 2825, 2023)

被引：1

作者：

Galsky, Matthew D.

Daneshmand, Siamak

Izadmehr, Sudeh

Gonzalez-Kozlova, Edgar

Chan, Kevin G.

Lewis, Sara

Achkar, Bassam El

Dorff, Tanya B.

Cetnar, Jeremy Paul

Neil, Brock O.

D'Souza, Anishka

Mamtani, Ronac

Kyriakopoulos, Christos

Jun, Tomi

Gogerly-Moragoda, Mahalya

Brody, Rachel

Xie, Hui

Nie, Kai

Kelly, Geoffrey

Horowitz, Amir

Kinoshita, Yayoi

Ellis, Ethan

Nose, Yohei

Ioannou, Giorgio

Cabal, Rafael

Del Valle, Diane M.

Haines, G. Kenneth

Wang, Li

Mouw, Kent W.

Samstein, Robert M.

Mehrazin, Reza

Bhardwaj, Nina

Yu, Menggang

Zhao, Qianqian

Kim-Schulze, Seunghee

Sebra, Robert

Zhu, Jun

Gnjatic, Sacha

Sfakianos, John

Pal, Sumanta K.

机构：

[1] Icahn School of Medicine at Mount Sinai,Division of Hematology and Medical Oncology

[2] Tisch Cancer Institute,Department of Urology

[3] Icahn School of Medicine at Mount Sinai,Department of Oncological Sciences

[4] Keck School of Medicine of USC,Department of Urology

[5] Norris Comprehensive Cancer Center,Department of Radiology

[6] Tisch Cancer Institute,Department of Medical Oncology & Therapeutics

[7] Icahn School of Medicine at Mount Sinai,Division of Hematology and Medical Oncology

[8] City of Hope Comprehensive Cancer Center,Department of Urology

[9] Tisch Cancer Institute,Division of Hematology and Medical Oncology

[10] Icahn School of Medicine at Mount Sinai,Division of Hematology and Medical Oncology

[11] City of Hope Comprehensive Cancer Center,Division of Hematology and Medical Oncology

[12] Oregon Health and Science University,Department of Pathology

[13] University of Utah,Department of Genetics and Genomic Sciences

[14] Keck School of Medicine of USC,Department of Pathology, Molecular and Cell

[15] Norris Comprehensive Cancer Center,based Medicine

[16] University of Pennsylvania Abramson Cancer Center,Department of Radiation Oncology

[17] University of Wisconsin Carbone Cancer Center,Department of Radiation Oncology

[18] Genentech,Department of Urology

[19] Tisch Cancer Institute,Department of Biostatistics and Medical Informatics

[20] Icahn School of Medicine at Mount Sinai,undefined

[21] Human Immune Monitoring Center,undefined

[22] Icahn School of Medicine at Mount Sinai,undefined

[23] Precision Immunology Institute,undefined

[24] Icahn School of Medicine at Mount Sinai,undefined

[25] Icahn School of Medicine at Mount Sinai,undefined

[26] Icahn Institute for Data Science and Genomic Technology,undefined

[27] Icahn School of Medicine at Mount Sinai,undefined

[28] Icahn School of Medicine at Mount Sinai,undefined

[29] Gene Dx,undefined

[30] Dana-Farber Cancer Institute/Brigham & Women’s Hospital,undefined

[31] Harvard Medical School,undefined

[32] Tisch Cancer Institute,undefined

[33] Icahn School of Medicine at Mount Sinai,undefined

[34] Tisch Cancer Institute,undefined

[35] Icahn School of Medicine at Mount Sinai,undefined

[36] University of Wisconsin Carbone Cancer Center,undefined

[37] Formerly with the Icahn School of Medicine at Mount Sinai,undefined

来源：

NATURE MEDICINE | 2024年 / 30卷 / 4期

关键词：

D O I：

10.1038/s41591-024-02814-0

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：1211 / 1211

页数：1

共 50 条

[31] Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
Galsky, Matthew D.
Pal, Sumanta K.
Chowdhury, Simon
Harshman, Lauren C.
Crabb, Simon J.
Wong, Yu-Ning
Yu, Evan Y.
Powles, Thomas
Moshier, Erin L.
Ladoire, Sylvain
Hussain, Syed A.
Agarwal, Neeraj
Vaishampayan, Ulka N.
Recine, Federica
Berthold, Dominik
Necchi, Andrea
Theodore, Christine
Milowsky, Matthew I.
Bellmunt, Joaquim
Rosenberg, Jonathan E.
CANCER, 2015, 121 (15) : 2586 - 2593
[32] PHASE 2 TRIAL OF NEOADJUVANT GEMCITABINE AND CARBOPLATIN FOR MUSCLE-INVASIVE BLADDER CANCER FOLLOWED BY RADICAL CYSTECTOMY
Koie, Takuya
Okamoto, Teppei
Imanishi, Kengo
Sugiyama, Naoki
Kudoh, Shigemasa
Mori, Kazuyuki
Tachiwada, Tokushi
Yoneyama, Takahiro
Hashimoto, Yasuhiro
Kamimura, Noritaka
Ohyama, Chikara
Suzuki, Yuichiro
JOURNAL OF UROLOGY, 2010, 183 (04): : E657 - E657
[33] Bladder-sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world study
Luo, Cheng
Luo, Shuhang
Wusimanjiang, Wumier
Wang, Zongren
Liu, Ping
Wang, Bin
Yuan, Dan
Lin, Hao
Xu, Abai
Deng, Nan
Wu, Kaihui
Zhu, Xuejin
Xu, Peng
Chen, Junxing
Huang, Bin
CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (07): : 1759 - 1767
[34] A PHASE 1/2 STUDY OF RAPAMYCIN AND CISPLATIN/GEMCITABINE FOR TREATMENT OF PATIENTS (PTS) WITH MUSCLE-INVASIVE BLADDER CANCER (NCT01938573)
Makrakis, Dimitrios
Roudier, Martine
Wang, Yan
Vakar-Lopez, Funda
Garcia, Jose
Dash, Atreya
Lin, Daniel
Schade, George
Mostaghel, Elahe A.
Cheng, Heather
Schweizer, Michael T.
Holt, Sarah K.
Gore, John L.
Yu, Evan
Lam, Hung-Ming
Wright, Jonathan L.
Montgomery, Bruce
JOURNAL OF UROLOGY, 2022, 207 (05): : E185 - E185
[35] Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial
Roger Li
Nancy Y. Villa
Xiaoqing Yu
Joseph O. Johnson
Gustavo Borjas
Jasreman Dhillon
Carlos M. Moran-Segura
Youngchul Kim
Natasha Francis
Denise Dorman
John J. Powers
Wade J. Sexton
Philippe E. Spiess
Michael A. Poch
Logan Zemp
Scott M. Gilbert
Jingsong Zhang
Julio M. Pow-Sang
Alexander R. A. Anderson
Tingyi Li
Xuefeng Wang
G. Daniel Grass
James M. Burke
Colin P. N. Dinney
Paulo C. Rodriguez
Rohit K. Jain
James J. Mulé
Jose R. Conejo-Garcia
Nature Medicine, 2025, 31 (1) : 176 - 188
[36] Phase II trial of neoadjuvant gemcitabine (G) and cisplatin (C) with sunitinib in patients (pts) with muscle-invasive bladder cancer (MIBC)
Balar, Arjun Vasant
Iyer, Gopa
Apolo, Andrea Borghese
Regazzi, Ashley Marie
Garcia-Grossman, Ilana Rebecca
Pendse, Deepa
Ostrovnaya, Irina
Chou, Joanne F.
Bochner, Bernard
Dalbagni, Guido
Herr, Harry W.
Milowsky, Matthew I.
Bajorin, Dean F.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[37] Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial
Funt, Samuel A.
Lattanzi, Michael
Whiting, Karissa
Al-Ahmadie, Hikmat
Quinlan, Colleen
Teo, Min Yuen
Lee, Chung-Han
Aggen, David
Zimmerman, Danielle
McHugh, Deaglan
Apollo, Arlyn
Durdin, Trey D.
Truong, Hong
Kamradt, Jeffrey
Khalil, Maged
Lash, Bradley
Ostrovnaya, Irina
McCoy, Asia S.
Hettich, Grace
Regazzi, Ashley
Jihad, Marwah
Ratna, Neha
Boswell, Abigail
Francese, Kaitlyn
Yang, Yuanquan
Folefac, Edmund
Herr, Harry W.
Donat, S. Machele
Pietzak, Eugene
Cha, Eugene K.
Donahue, Timothy F.
Goh, Alvin C.
Huang, William C.
Bajorin, Dean F.
Iyer, Gopa
Bochner, Bernard H.
Balar, Arjun V.
Mortazavi, Amir
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (12) : 1312 - +
[38] Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer
Hattori, Yuto
Fujiwara, Tasuku
Hagimoto, Hiroki
Kokubun, Hidetoshi
Murata, Shiori
Makita, Noriyuki
Abe, Yohei
Kubota, Masashi
Tohi, Yoichiro
Tsutsumi, Naofumi
Shibasaki, Noboru
Inoue, Koji
Kawakita, Mutsushi
Yamasaki, Toshinari
INTERNATIONAL JOURNAL OF UROLOGY, 2024,
[39] Neoadjuvant sintilimab combined with gemcitabine and cisplatin (GP) for muscle-invasive bladder cancer (MIBC) patients followed by selective bladder sparing surgery
Tong, Z.
Fu, G.
Zhou, F.
Liu, X.
Xue, X.
Zhang, H.
Wang, Y.
Zhu, X.
Gao, Y.
Liu, L.
Bao, X.
Zheng, Y.
Fang, W.
Zhao, P.
Jin, B.
ANNALS OF ONCOLOGY, 2023, 34 : S1210 - S1210
[40] Role of adjuvant intravesical chemotherapy in the combined organ-sparing treatment of non-muscle-invasive bladder cancer
Zubkov, A. Yu.
Nuriev, I. R.
Sitdykov, E. N.
ONKOUROLOGIYA, 2014, 10 (02): : 26 - 28

← 1 2 3 4 5 →